Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

CAR-T Meeting 2023 | Moving CAR-T therapy to earlier lines in multiple myeloma and clinical trials in this space

Hermann Einsele • 10 Feb 2023
CAR-T Meeting 2023
Multiple Myeloma CAR-T
CARTITUDE-2 CARTITUDE-6 KarMMa-2

In this video, Hermann Einsele, MD, FRCP, University Hospital of Würzburg, Würzburg, Germany, discusses the benefits of moving CAR-T therapy to earlier lines of treatment in multiple myeloma, and further highlights clinical trials exploring this, including CARTITUDE-2 (NCT04133636), KarMMa-2 (NCT03601078), and CARTITUDE-6 (NCT05257083). This interview took place at the EBMT-EHA 5th European CAR T-cell Meeting held in Rotterdam, The Netherlands.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Hermann Einsele

2:44
Moving CAR-T into earlier lines of therapy in multiple myeloma
Hermann Einsele • 17 Feb 2024
0:45
CAR T-cell therapy in lenalidomide-refractory multiple myeloma
Hermann Einsele • 17 Feb 2024
1:19
Sequencing bispecific antibodies and CAR-T therapy & the evolving role of bispecifics in myeloma
Hermann Einsele • 26 Jun 2023
8:16
Results from CARTITUDE-4: cilta-cel for lenalidomide-refractory multiple myeloma
Hermann Einsele • 26 Jun 2023

Related Videos

1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
3:23
Molecular characteristics associated with increased risk of disease progression in SMM
Mark Bustoros • 27 Sep 2023
The content of VJHemOnc is intended for healthcare professionals